Company Quick10K Filing
Asterias Biotherapeutics
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 0 $0
10-Q 2018-09-30 Quarter: 2018-09-30
10-Q 2018-06-30 Quarter: 2018-06-30
10-Q 2018-03-31 Quarter: 2018-03-31
10-K 2017-12-31 Annual: 2017-12-31
10-Q 2017-09-30 Quarter: 2017-09-30
10-Q 2017-06-30 Quarter: 2017-06-30
10-Q 2017-03-31 Quarter: 2017-03-31
10-K 2016-12-31 Annual: 2016-12-31
10-Q 2016-09-30 Quarter: 2016-09-30
10-Q 2016-06-30 Quarter: 2016-06-30
10-Q 2016-03-31 Quarter: 2016-03-31
10-K 2015-12-31 Annual: 2015-12-31
10-Q 2015-09-30 Quarter: 2015-09-30
10-Q 2015-06-30 Quarter: 2015-06-30
10-Q 2015-03-31 Quarter: 2015-03-31
10-K 2014-12-31 Annual: 2014-12-31
10-Q 2014-09-30 Quarter: 2014-09-30
10-Q 2014-06-30 Quarter: 2014-06-30
10-Q 2014-03-31 Quarter: 2014-03-31
10-K 2013-12-31 Annual: 2013-12-31
8-K 2019-03-07 M&A, Shareholder Rights, Control, Officers, Amend Bylaw, Shareholder Vote, Exhibits
8-K 2019-03-01 Other Events
8-K 2018-11-07 Enter Agreement, Officers, Other Events, Exhibits
8-K 2018-09-28 Enter Agreement, Leave Agreement, Off-BS Arrangement, Other Events
8-K 2018-09-17 Officers
8-K 2018-06-20 Shareholder Vote

Asterias Biotherapeutics Financials

-

AST Metrics, Comps, Filings


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Stockholders' Equity

Income Statement ($MM Quarter)

Revenue, Gross Profit, Net Income

Cash Flow ($MM Quarter)

Operating, Investing, Financing

Comps ($'000 TTM) Market Cap Assets Liabilities Revenue Gross Profit Net Income EBITDA EV
Arsanis (ASNS) 29,581 133,507 37,339 3,500 0 -22,768 -21,230 -39,343
Cidara Therapeutics (CDTX) 44,703 51,752 19,970 0 0 -56,069 -55,651 130
Xtant Medical Holdings (XTNT) 32,125 44,497 85,573 67,526 39,499 -64,228 -53,862 98,746
Ampliphi Biosciences (APHB) 2,988 34,916 12,286 0 0 -13,742 -13,208 -10,904
Protalix Biotherapeutics (PLX) 55,242 122,727 663 -1,254 -20,770 -16,381 -25,096
Organovo Holdings (ONVO) 57,323 43,451 7,312 3,070 2,608 -25,542 -24,645 21,757
Neuralstem (CUR) 311 3,522 1,559 0 0 -6,702 -6,545 -1,971
Vical (VICL) 19,415 42,701 1,159 171 0 -12,124 -12,004 8,602
Tracon Pharmaceuticals (TCON) 23,950 27,951 19,032 0 0 -30,380 -30,353 4,614
Cytrx (CYTR) 11,100 19,942 1,855 250 0 -8,329 -7,551 -8,277
Aevi Genomic Medicine (GNMX) 11,658 4,021 3,689 0 0 -22,359 -22,359 8,221
Vaxart (VXRT) 11,208 37,250 21,405 7,455 0 -18,426 -13,768 -5,092
Trovagene (TROV) 13,984 13,868 5,020 467 440 -15,958 -15,494 3,193
Titan Pharmaceuticals (TTNP) 18,683 6,761 7,332 3,832 3,060 -15,263 -14,984 20,422
Proteon Therapeutics (PRTO) 8,030 11,600 2,123 0 0 -21,615 -21,615 -2,805
Microbot Medical (MBOT) 3,317 12,575 4,594 0 0 -7,381 -7,381 -5,812
Aptose Biosciences (APTO) 38,190 4,434 0 0 -17,985 -17,903 -26,898
Cellular Biomedicine Group (CBMG) 190,535 117,687 35,510 145 78 -42,696 -38,564 133,821
Biondvax Pharmaceuticals (BVXV) 0 105,837 0 0 0 0 -707
Asterias Biotherapeutics (AST) 29,814 5,309 731 540 -20,296 -18,593 -6,524

Balance Sheet ($'000)2013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-30
Cash922,17132612,8615,0253,0767,42115,63612,64511,1837,60021,46917,92619,80018,05911,8758,62013,26610,5199,3176,524
Accounts Receivable
Inventory
PP&E1,5751,6811,7781,8791,8811,7961,8121,9551,9907,0725,5395,3725,2127,9667,9808,0467,3347,3877,3807,3801,793
Assets1,85080,35472,01361,87953,19444,11452,50360,31654,37166,97854,65067,24470,30361,01057,22148,56243,32043,09239,32734,34329,814
Accounts Payable5674862543867371,1321,3893997471,9062516401,076737408311401
Long-Term Debt
Liabilities6,98126,57323,02328,18019,29211,48213,97113,64712,20321,87921,31923,97027,57718,98212,75911,84711,5889,5496,3236,2715,309
Stockholders' Equity
Income Statement ($'000)2013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-30
Revenue06221851,0567797721,4236081,5941,5322,0761,7522,0103161,68828478109116
Cost of Revenue41421151381763536591053188114635757
Gross Profit-21421,0457287341,2476051,5411,5262,0171,7421,9572981,607144155259
R&D1,1492,3882,5992,7432,5685,4003,5933,6964,6295,4036,3436,0195,2327,8736,5986,9846,6246,4343,6263,6173,510
SG&A
Tax-1,349-1,513-2,313-2,201-1,584-1,241-1,561-2,866-902-451-902-700000
Net Income-2,669-17,565-2,287-2,802-1,682-3,326-2,973-3,618-3,507-4,905-10,337-5,159-10,648-9,345-6,287-8,728-6,809-6,548-2,312-6,982-4,454
Cash Flow ($'000)2013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-30
Cash Operating-7612,585-1,449-485-7,834-4,524-5,785-3,936-3,193-2,908
Cash Investing01,354-39612,553-21236781,483998257
Cash Financing761-859046801,1469,753-294993-142